Cargando…
Tofacitinib Treatment in Primary Herpes Simplex Encephalitis Interferes With Antiviral Response
Tofacitinib, a Janus kinase inhibitor, is a novel immunosuppressive drug for treatment of rheumatoid arthritis. Herpes simplex virus type 1 (HSV-1) may cause encephalitis during primary infection or following reactivation from a latent state. Long-term tofacitinib treatment may increase the risk of...
Autores principales: | Krzyzowska, Malgorzata, Jarneborn, Anders, Thorn, Karolina, Eriksson, Kristina, Jin, Tao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635063/ https://www.ncbi.nlm.nih.gov/pubmed/35217873 http://dx.doi.org/10.1093/infdis/jiac040 |
Ejemplares similares
-
CD8(+) T cells in the central nervous system of mice with herpes simplex infection are highly activated and express high levels of CCR5 and CXCR3
por: Lind, Liza, et al.
Publicado: (2021) -
CXCL11 production in cerebrospinal fluid distinguishes herpes simplex meningitis from herpes simplex encephalitis
por: Lind, Liza, et al.
Publicado: (2017) -
Effect of combinations of antiviral drugs on herpes simplex encephalitis
por: Gebhardt, Bryan M, et al.
Publicado: (2009) -
When herpes simplex virus encephalitis meets antiviral innate immunity
por: Zhang, Linhai, et al.
Publicado: (2023) -
Incidence, Duration, and Risk Factors Associated With Missed Opportunities to Diagnose Herpes Simplex Encephalitis: A Population-Based Longitudinal Study
por: Miller, Aaron C, et al.
Publicado: (2021)